SMITHS FALLS, ON, Aug. 9, 2019 /PRNewswire/ – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED), (NYSE: CGC) is pleased to announce that it has entered into an agreement to acquire the global cannabinoid-based medical researcher Beckley Canopy Therapeutics (“Beckley Canopy”). The acquisition brings together Canopy’s wholly owned research program with the Beckley Canopy research platform which is partly owned by Canopy Growth in order to combine the best teams, programs and clinical work all under a single strategic plan. The research arm in turn directly supports the commercial efforts of Spectrum Therapeutics around the world. As part of the acquisition, Canopy Growth also acquires the outstanding shares in Spectrum Biomedical UK, the commercial arm of the Company in the United Kingdom, as that markets begins to develop into a commercially viable opportunity.
With the acquisition of C3, and Canopy Growth’s expanding
... read more at: https://www.prnewswire.com/news-releases/canopy-growth-strengthens-position-as-global-cannabis-research-leader-by-entering-agreement-to-acquire-beckley-canopy-therapeutics-300899310.html